

Market Review

July 2021

How the different asset classes have fared:

(As at 31 July 2021)

Asset Class	10 Yr % p.a.	5 Yr % p.a.	3 Yr % p.a.	1 Yr % p.a.	YTD %	6 Mth %	3 Mth %	1 Mth %
Cash	2.2	1.3	0.9	0.1	0.0	0.0	0.0	0.0
Australian Bonds	5.0	3.4	4.8	0.5	0.0	0.4	2.7	1.8
International Bonds	5.3	3.0	4.5	0.1	-0.4	0.2	2.0	1.3
Australian Shares	9.9	10.4	10.2	30.4	13.8	13.4	5.7	1.1
Int. Shares Unhedged	15.9	15.3	15.2	31.9	21.0	21.5	10.2	4.1
Int. Shares Hedged	13.4	14.0	13.0	33.7	16.3	17.2	5.2	1.8
Emerging Markets Unhedged	7.5	10.6	7.8	17.0	4.9	1.3	0.3	-4.8
Listed Infrastructure Unhedged	13.2	7.6	7.6	14.2	13.7	15.8	5.6	4.2
Australian Listed Property	12.8	5.2	8.1	33.7	10.6	15.3	7.9	0.5
Int. Listed Pty Unhedged	11.3	4.6	7.9	33.1	28.4	28.0	12.1	6.4

1 Bloomberg AusBond Bank 0+Y TR AUD, 2 Bloomberg AusBond Composite 0+Y TR AUD, 3 Bloomberg Barclays Global Aggregate TR Hdg AUD, 4 S&P/ASX All Ordinaries TR, 5 Vanguard International Shares Index, 6 Vanguard Intl Shares Index Hdg AUD TR, 7 Vanguard Emerging Markets Shares Index, 8 FTSE Developed Core Infrastructure 50/50 NR AUD, 9 S&P/ASX 300 AREIT TR, 10 FTSE EPRA/NAREIT Global REITs NR AUD

International Equities

International share markets (unhedged) rose by 4.1% in July. The weaker A\$ helped with hedged international shares which did not benefit from the falling A\$ only returning 1.8%. The US share market continues to edge higher. European shares also delivered positive returns. Chinese and Hong Kong share markets experienced a more difficult period; with concerns rising amongst property developers who are facing government restrictions on their capacity to borrow; and big Chinese technology companies who seem to have fallen out of favour with

the Chinese authorities.

Overall, share markets continued to be underpinned by a strong recovery, due to the ongoing rollout of vaccines and lower long-term interest rates. However, there are some areas of concern. Market breadth which measures participation in the market is becoming narrower, with fewer and fewer large capitalization stocks responsible for driving the market higher.

Australian Equities

The S&P/ASX All Ordinaries Index rose by 1.1% in July, supported by continued strength in the domestic economy. Sentiment remains positive despite the widening round of Covid-19 related lockdowns in Sydney and other capitals. Unlike the first round of lockdowns there are not aggressive stimulus packages in place. A key issue for both the Australian share market and the Australian economy is just how quickly Australia can roll out its vaccination program. There are some grounds for optimism, with additional vaccine supplies becoming available.

Domestic and International Fixed Income

Australian government bond yields and US Treasury yields both moved lower in June, leading to capital gains in fixed interest markets. The RBA has quite clearly indicated that Australian cash rates are likely to be held at current levels for at least the next few years. The rise in capital values for bonds and most fixed interest funds is welcome. Investors depending on fixed interest investments to deliver income, will continue to experience low levels of interest rates over the coming periods.

Australian Dollar

The Australian dollar fell by around 2% against the US dollar in July and is now lower for the calendar year to date, amid broad US dollar strength. The US dollar rose against most currencies.

Disclaimer

The information contained in this material is current as at date of publication unless otherwise specified and is provided by ClearView Financial Advice Pty Ltd ABN 89 133 593 012, AFS Licence No. 331367 (ClearView) and Matrix Planning Solutions Limited ABN 45 087 470 200, AFS Licence No. 238 256 (Matrix). Any advice contained in this material is general advice only and has been prepared without taking account of any person's objectives, financial situation or needs. Before acting on any such information, a person should consider its appropriateness, having regard to their objectives, financial situation and needs. In preparing this material, ClearView and Matrix have relied on publicly available information and sources believed to be reliable. Except as otherwise stated, the information has not been independently verified by ClearView or Matrix. While due care and attention has been exercised in the preparation of the material, ClearView and Matrix give no representation, warranty (express or implied) as to the accuracy, completeness or reliability of the information. The information in this document is also not intended to be a complete statement or summary of the industry, markets, securities or developments referred to in the material. Any opinions expressed in this material, including as to future matters, may be subject to change. Opinions as to future matters are predictive in nature and may be affected by inaccurate assumptions or by known or unknown risks and uncertainties and may differ materially from results ultimately achieved. Past performance is not an indicator of future performance.